文献速递儿童血液肿瘤与免疫

儿童混合表型急性白血病29例诊治与疗效分析

[Diagnosis and treatment efficacy analysis of 29 children with mixed phenotype acute leukemia].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2020-01-01

回顾性分析29例儿童混合表型急性白血病(MPAL)的临床特征与预后。27例接受诱导化疗,完全缓解率85%(23/27),5年无病生存率(71±10)%,5年总生存率(74±10)%。ALL方案与联合方案诱导的5年OS无显著差异(P=0.870)。

要点

  • 儿童MPAL中B/髓型13例、T/髓型12例,常见CD33、CD34、HLA-DR阳性。
  • 27例获染色体核型者中14例异常,10例为复杂核型。
  • ALL或联合方案诱导化疗CR率85%,5年OS(74±10)%。

核心结论

  • MPAL是罕见儿童白血病,易见复杂染色体核型,ALL方案及混合方案诱导化疗可获得较好预后。

研究设计与样本

  • 回顾性分析2005年1月1日至2019年12月1日中国医学科学院血液病医院儿童血液病诊疗中心29例MPAL患儿。
  • 分析形态学、免疫表型、细胞遗传学、分子生物学特点、诱导化疗及预后,Kaplan-Meier法绘制生存曲线,Log-Rank法单因素分析。

主要发现

  • 29例中1例MPAL伴KMT2A重排,1例MPAL伴BCR-ABL1,13例MPAL伴B-M,12例MPAL伴T-M,2例急性未分化细胞白血病。
  • 免疫表型阳性率:CD33 23例(79%)、CD34 25例(86%)、HLA-DR 20例(69%)、CD19 17例(59%)。
  • 8例检测到异常融合基因:MLL-AF4 1例、BCR-ABL1 1例、TEL-AML1 3例、WT1 2例、FLT3-ITD阳性1例。
  • 27例获得染色体核型,14例异常核型,其中10例为复杂核型。
  • 接受化疗27例中CR率85%(23/27),5年DFS(71±10)%,5年OS(74±10)%。

关键数值与推荐

  • 14例应用ALL方案者中13例CR,12例应用联合方案者中10例CR。
  • ALL方案与联合方案5年OS分别为(77±15)%和(80±13)%,差异无统计学意义(χ²=0.027,P=0.870)。

临床怎么用

  • 儿童MPAL应完善免疫表型、细胞遗传学及分子生物学检查以明确分型。
  • 诱导化疗可选择ALL方案或联合方案,二者5年OS无显著差异。

局限性

  • 为单中心回顾性研究,样本量29例,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the clinical characteristics and prognosis of mixed phenotype acute leukemia (MPAL) in children. Methods: The data of 29 children diagnosed as MPAL in the Pediatric Blood Disease Center, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences from January 1, 2005 to December 1, 2019 were collected retrospectively. The morphology, immunophenotypes, cytogenetics, molecular biological characteristics, induction chemotherapy regimen, and prognosis were analyzed. Kaplan-Meier Method was used to draw survival curve. Log-Rank was used for univariate analysis. Results: (1) Among 29 MPAL cases, there were 1 case with KMT2A rearrangement, 1 case with BCR-ABL1, 13 cases with B/myeloid(B-M) type, 12 cases with T/myeloid(T-M) type and 2 cases with acute undifferentiated leukemia. (2) The common immunophenotypes were CD33 (23 cases, 79%), CD34 (25 cases, 86%) and HLA-DR (20 cases, 69%), and CD19 was positive in 17 cases (59%). (3) In molecular genetics analysis, 8 cases were detected to have abnormal gene fusion, including 1 case with MLL-AF4 fusion gene, 1 case with BCR-ABL1 fusion gene, 3 cases with TEL-AML1 fusion gene, 2 cases with WT1 and 1 case with FLT3-ITD. (4) In cytogenetics analysis, 27 cases obtained chromosome karyotypes, including 14 cases with abnormal karyotypes and 10 cases were complex karyotypes. (5) In treatment efficacy analysis, 27 cases received induction chemotherapy and the complete remission(CR) rate was 85%(23/27).The 5-year disease free survival(DFS) rate was (71±10)% and 5-year overall survival(OS) rate was (74±10)%. Thirteen of 14 cases received acute lymphoblastic leukemia(ALL) induction therapy achieved CR, while 10 of 12 cases received hybrid induction therapy achieved CR. No significant difference was found in 5 year-OS rates between cases with ALL induction therapy and hybrid induction therapy ((77±15)% vs. (80±13)%, χ²=0.027,P=0.870). Conclusions: MPAL is a rare childhood leukemia and is prone to incorporate complex karyotypes. Induction therapy with ALL or hybrid regimens is a good choice to obtain favorable prognosis. 目的: 分析混合表型急性白血病(MPAL)的临床特征及疗效预后。 方法: 回顾性分析2005年1月1日至2019年12月1日就诊于中国医学科学院血液病医院儿童血液病诊疗中心的29例MPAL患儿,分析其形态学、免疫表型、细胞遗传学、分子生物学特点、诱导化疗以及预后情况。应用Kaplan-Meier法绘制生存曲线,单因素分析应用Log-Rank法。 结果: (1)29例MPAL患儿中1例为MPAL伴KMT2A重排,1例为MPAL伴BCR-ABL1,13例为MPAL伴B-M,12例为MPAL伴T-M, 2例为急性未分化细胞白血病。(2)免疫表型阳性率较高的是CD33 23例(79%),CD34 25例(86%),HLA-DR 20例(69%)。表达CD19的共17例,阳性率59%。(3)8例患儿检测到异常融合基因,其中MLL-AF4基因1例,BCR-ABL1基因1例,TEL-AML1基因3例,WT1 2例,FLT3-ITD 阳性1例。(4)27例获得染色体核型,14例为异常核型,其中10例为复杂核型。(5)接受化疗的27例患儿中完全缓解(CR)率为85%(23/27),5年无病生存率(DFS)为(71±10)%,5年总生存率(OS)为(74±10)%。14例应用急性淋巴细胞白血病(ALL)方案者中13例CR;12例应用联合方案者中10例CR;二者5年OS分别为(77±15)%和(80±13)%,差异无统计学意义(χ²=0.027,P=0.870)。 结论: MPAL是一种罕见的儿童白血病,易见复杂染色体核型,ALL方案及混合方案诱导缓解化疗可获得较好的预后。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen X, Liu F, Guo Y, et al. [Diagnosis and treatment efficacy analysis of 29 children with mixed phenotype acute leukemia]. Zhonghua Er Ke Za Zhi. 2020. PMID: 32987459. doi:10.3760/cma.j.cn112140-20200430-00454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。